AMG 531: an investigational thrombopoiesis-stimulating peptibody

Pediatr Blood Cancer. 2006 Oct 15;47(5 Suppl):723-5. doi: 10.1002/pbc.20972.

Abstract

Thrombopoietin (TPO) regulates megakaryopoiesis and the generation of platelets. Recombinant TPO has been investigated in clinical studies for use in thrombocytopenia with limited success. A new peptibody, AMG 531, has been shown to increase platelet counts in preclinical and Phase 1 and Phase 2 studies and to be generally safe and tolerable in those studies.

Publication types

  • Review

MeSH terms

  • Animals
  • Carrier Proteins / administration & dosage
  • Carrier Proteins / immunology
  • Carrier Proteins / therapeutic use*
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Dose-Response Relationship, Drug
  • Humans
  • Placebos
  • Platelet Count
  • Purpura, Thrombocytopenic, Idiopathic / drug therapy*
  • Purpura, Thrombocytopenic, Idiopathic / immunology
  • Randomized Controlled Trials as Topic
  • Receptors, Fc / administration & dosage
  • Receptors, Fc / immunology
  • Receptors, Fc / therapeutic use*
  • Recombinant Fusion Proteins
  • Thrombopoiesis / drug effects*
  • Thrombopoiesis / immunology
  • Thrombopoietin

Substances

  • Carrier Proteins
  • Placebos
  • Receptors, Fc
  • Recombinant Fusion Proteins
  • Thrombopoietin
  • romiplostim